Concord Biotech has successfully commissioned and commenced production of injectable at its new manufacturing facility situated at Valthera. This advanced facility has been designed and constructed to adhere to stringent international standards, equipped with cutting-edge technology to ensure the consistent delivery of high-quality products. The operationalization of Unit-4 is a part of company's strategic growth initiatives.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
